HOWL
Werewolf Therapeutics, Inc.Company Information
- Company Name
- Werewolf Therapeutics, Inc.
- CIK
- CIK0001785530
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- HOWL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- HOWL
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-14
- Last sale
- 2026-07-07
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 4,057,065
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 10,791,925
- Shares outstanding
- 48,597,534
- Ownership
- 22.21%
Earnings Market Reaction
- Filing date
- 2026-07-31
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 22 | 46 | 57 | 66 | 78 | 92 | 111 | 123 | 135 | 139 | 134 | 130 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | ||||||
| Assets Current | 23 | 49 | 59 | 68 | 80 | 94 | 113 | 126 | 139 | 142 | 138 | 139 | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 6 | ||||||
| Property Plant And Equipment Net | 1 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 8 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 21 | 21 | 21 | ||||||
| Operating Lease Right Of Use Asset | 0 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Assets | 24 | 58 | 69 | 80 | 93 | 107 | 127 | 140 | 154 | 178 | 175 | 176 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 1 | 1 | 3 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 6 | 5 | 5 | 9 | 9 | 9 | 11 | 10 | 9 | 6 | 9 | 8 | ||||||
| Operating Lease Liability Current | 0 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | ||||||
| Notes Payable Current | 0 | 29 | 28 | 6 | 2 | - | 0 | 0 | 0 | 12 | 7 | 2 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 | 2 | ||||||
| Liabilities Current | 8 | 39 | 36 | 18 | 15 | 12 | 15 | 12 | 11 | 21 | 19 | 14 | ||||||
| Operating Lease Liability Noncurrent | 0 | 7 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 11 | 11 | 11 | ||||||
| Long Term Notes Payable | - | - | 0 | 22 | 25 | 27 | 26 | 26 | 25 | 28 | 33 | 38 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Derivative Liabilities | - | - | - | - | - | - | - | 3 | 3 | - | - | - | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 1 | 3 | 3 | 3 | 3 | - | - | - | 0 | - | ||||||
| Liabilities | 8 | 46 | 45 | 50 | 51 | 50 | 54 | 51 | 50 | 60 | 63 | 64 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 502 | 501 | 500 | 497 | 492 | 490 | 488 | 484 | 482 | 478 | 455 | 445 | ||||||
| Retained Earnings Accumulated Deficit | -485 | -489 | -475 | -467 | -451 | -433 | -415 | -394 | -378 | -360 | -344 | -332 | ||||||
| Stockholders Equity | 16 | 12 | 25 | 30 | 41 | 57 | 73 | 89 | 104 | 118 | 111 | 112 | ||||||
| Liabilities And Stockholders Equity | 24 | 58 | 69 | 80 | 93 | 107 | 127 | 140 | 154 | 178 | 175 | 176 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 49 | 49 | 49 | 47 | 45 | 45 | 45 | 44 | 44 | 43 | 39 | 36 | ||||||
| Shares Outstanding | 49 | 49 | 49 | 47 | 45 | 45 | 45 | 44 | 44 | 43 | 39 | 36 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialWerewolf Therapeutics, Inc. (HOWL) — SEC Financial Statements & Analysis
Werewolf Therapeutics, Inc. (HOWL) is a pharmaceutical preparations company, incorporated in DE. Werewolf Therapeutics, Inc. trades on Nasdaq as: HOWL. Werewolf Therapeutics, Inc. (HOWL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31. Based on that filing, Werewolf Therapeutics, Inc. carries a market cap of $17.50M, a P/E ratio of -0.51x, a P/B ratio of 1.07x, an enterprise value of $-4.49M, and an EV/EBITDA multiple of 0.16x. On profitability, it posts a Return on Equity (ROE) of -119.86%, a Return on Assets (ROA) of -59.31%, and a Return on Invested Capital (ROIC) of -1025.43%. Per share, it reports EPS of $-0.71, diluted EPS of $-0.71, free cash flow per share of $-0.62, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -52.68% year-over-year and EPS growth of -56.20% year-over-year. On the balance sheet, it maintains a current ratio of 2.91x, a quick ratio of 2.80x, working capital of $15.03M, a debt-to-equity ratio of 0.48x, a debt ratio of 0.33, an interest coverage ratio of -6.87x, free cash flow of $-30.15M (TTM), and net debt of $-21.99M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.50M
- P/E TTM
- -0.51x
- EPS TTM
- $-0.71
- P/B TTM
- 1.07x
- ROE TTM
- -119.86%
- ROA TTM
- -59.31%
- Debt To Equity
- 0.48x
- Free Cash Flow TTM
- $-30.15M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Werewolf Therapeutics, Inc. in?
Werewolf Therapeutics, Inc. (HOWL) operates in the Pharmaceutical Preparations industry.
What exchange does HOWL trade on?
Werewolf Therapeutics, Inc. (HOWL) trades on the Nasdaq.
Where is Werewolf Therapeutics, Inc. incorporated?
Werewolf Therapeutics, Inc. is incorporated in DE.
When was Werewolf Therapeutics, Inc. (HOWL)'s most recent SEC filing?
Werewolf Therapeutics, Inc. (HOWL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-31.
What is HOWL's market cap?
Werewolf Therapeutics, Inc. (HOWL) has a market capitalization of $17.50M as of 2026-06-30.
What is HOWL's EPS (earnings per share)?
Werewolf Therapeutics, Inc. (HOWL)'s trailing twelve month EPS is $-0.71 as of 2026-06-30.
What is HOWL's ROE (return on equity)?
Werewolf Therapeutics, Inc. (HOWL)'s trailing twelve month Return on Equity (ROE) is -119.86% as of 2026-06-30.
What is HOWL's ROA (return on assets)?
Werewolf Therapeutics, Inc. (HOWL)'s trailing twelve month Return on Assets (ROA) is -59.31% as of 2026-06-30.
What is HOWL's ROIC (return on invested capital)?
Werewolf Therapeutics, Inc. (HOWL)'s trailing twelve month Return on Invested Capital (ROIC) is -1025.43% as of 2024-03-31.
What is HOWL's EV/EBITDA?
Werewolf Therapeutics, Inc. (HOWL)'s trailing twelve month EV/EBITDA is 0.16x as of 2026-06-30.